Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor

International Journal of Molecular Sciences

Elisabeth Ersvaer¹  Øystein Bruserud²  Guro Kristin Melve³  Tor Hervig³  Einar K. Kristoffersen³  Çiğdem Akalın Akkök⁴  Aymen Bushra Ahmed⁵ 

[1] Department of Biomedical Laboratory Sciences and Chemical Engineering, Faculty of Engineering and Business Administration, Bergen University College, N-5020 Bergen, Norway;Department of Clinical Science, University of Bergen, N-5020 Bergen, Norway;Department of Immunology and Transfusion Medicine, Haukeland University Hospital, N-5021 Bergen, Norway;Department of Immunology and Transfusion Medicine, Oslo University Hospital, Ullevål, N-0424 Oslo, Norway;Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway;

关键词: allogeneic transplantation;    hematopoietic stem cell mobilization;    granulocyte colony-stimulating factor;    osteopontin;    apheresis;   

DOI  :  10.3390/ijms17071158

来源: DOAJ

【 摘 要 】

Peripheral blood stem cells from healthy donors mobilized by granulocyte colony-stimulating factor (G-CSF) and harvested by leukapheresis are commonly used for allogeneic stem cell transplantation. The frequency of severe graft versus host disease is similar for patients receiving peripheral blood and bone marrow allografts, even though the blood grafts contain more T cells, indicating mobilization-related immunoregulatory effects. The regulatory phosphoprotein osteopontin was quantified in plasma samples from healthy donors before G-CSF treatment, after four days of treatment immediately before and after leukapheresis, and 18–24 h after apheresis. Myeloma patients received chemotherapy, combined with G-CSF, for stem cell mobilization and plasma samples were prepared immediately before, immediately after, and 18–24 h after leukapheresis. G-CSF treatment of healthy stem cell donors increased plasma osteopontin levels, and a further increase was seen immediately after leukapheresis. The pre-apheresis levels were also increased in myeloma patients compared to healthy individuals. Finally, in vivo G-CSF exposure did not alter T cell expression of osteopontin ligand CD44, and in vitro osteopontin exposure induced only small increases in anti-CD3- and anti-CD28-stimulated T cell proliferation. G-CSF treatment, followed by leukapheresis, can increase systemic osteopontin levels, and this effect may contribute to the immunomodulatory effects of G-CSF treatment.

【 授权许可】

Unknown